Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 111Neoplasms 22Neoplasm Metastasis 17Brain Neoplasms 15Breast Neoplasms, Male 13Head and Neck Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 5Glioblastoma 5Colorectal Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Inflammatory Breast Neoplasms 4Carcinoma, Ovarian Epithelial 4Salivary Gland Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioma 3Ependymoma 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumors 2Recurrence 2Osteitis Deformans 2Oligodendroglioma 2Neuroma, Acoustic 2Neurofibromatosis 2 2Gallbladder Neoplasms 2Esophageal Neoplasms 2

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER-2 Gene Amplification × Lapatinib × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡